Breast cancer is the commonest cancer and the leading cause of cancer death in women. It accounts for 22% of all female cancers ([@bib23]). More than 42 000 women in the United Kingdom are diagnosed with breast cancer each year and ∼80% survive at least 5 years ([@bib3]).

The prognosis of breast cancer is influenced by well-recognised host- and tumour-related factors including patient age, histological type and grade, tumour size, lymph node status, oestrogen receptor (ER) and progesterone receptor (PR) status, and human epidermal growth factor receptor 2 (HER-2) status ([@bib14]).

There is now good evidence that the development of cancer and its progression are dependent of a complex interaction of the tumour and the host inflammatory response ([@bib26]; [@bib10]; [@bib6]; [@bib12]). In particular, the local inflammatory response represents the interaction between the tumour and the host. A number of inflammatory cell types have been implicated in this response ([@bib20]). For example, our previous work using simple routine pathology haematoxylin and eosin (H&E) slides showed that lymphocytes were the most prominent cells infiltrating and had independent prognostic value in patients with primary operable invasive ductal breast cancer. In contrast, plasma cells (subtype of B lymphocytes) were associated with poorer survival ([@bib19]).

However, despite the large number of studies and considerable effort over a 50-year period, the relationship between different aspects of lymphocyte subsets infiltrate and outcome in primary operable breast cancer remains unclear. Although a number of studies over these years have attempted to examine these relationships, there have been conflicting results. For example, out of a total of 18 studies, 5 studies reported an association between T-lymphocyte subsets infiltrate and improved survival, 4 reported no association and 9 reported an association between T-lymphocytes subsets and poorer survival ([@bib20]). With reference to B lymphocytes, out of a total of 7 studies, 4 studies reported an association between B-lymphocyte subsets infiltrate and improved survival, 2 reported no association and 1 reported an association between B-lymphocyte subsets and poorer survival ([@bib20]).

An important potential confounder in previous work is that the immune context has rarely been taken into account. For example, where there is a dense tumour inflammatory cell infiltrate, the presence of a variety of inflammatory cell types is likely to reflect the activity of a coordinated immune response. In contrast, where there is a sparse inflammatory cell infiltrate, the presence of inflammatory cell types is likely to be associated with a different immune response. To date, few studies have considered this in their analysis of the relationship between individual inflammatory cell types and outcome.

Therefore, in this context, it is of considerable interest to examine lymphocytic infiltration using more sophisticated techniques to better understand the nature of such relationship between the tumour infiltrate and breast cancer outcome. Most tumour infiltrating lymphocytes are recognised to be of the CD3+ T-lymphocyte phenotype. This phenotype includes tumour CD4+ T lymphocytes and CD8+ cytotoxic T lymphocytes. In the normal state, CD4+ is expressed on ∼60% of mature T lymphocytes, whereas CD8+ is expressed on 30% of mature T lymphocytes giving an approximate 2 : 1 ratio.

Also, B lymphocytes have an important role in the humoral immune response and are responsible for both antigen presentation as well as antibody production. A common marker used to assess B lymphocytes is CD20+ that is expressed on B-lymphocyte precursors and mature B lymphocytes but lost during terminal plasma cell differentiation ([@bib25]), whereas monoclonal antibodies of the CD138+ have been developed and appear to be plasma cell-specific among hematopoietic elements ([@bib7]).

The aim of the present study was to examine the relationship, in the context of low- and high-grade generalised inflammatory cell infiltrate, between tumour lymphocyte subset infiltrate and standard clinico-pathological factors including hormone status (ER, PR and HER-2), Ki-67, lymphovascular invasion and survival in patients with primary operable invasive ductal breast cancer. In particular, to test the hypothesis that different lymphocyte subsets would have a different relationship with long-term outcome.

Patients and methods
====================

Patients presenting with invasive ductal breast cancer at Royal Infirmary, Western Infirmary and Stobhill Hospital, Glasgow, between 1995 and 1998 were studied (*n*=338). Clinico-pathological data included age, histological tumour type, grade, tumour size, lymph node status, lymphovascular invasion, type of surgery and use of adjuvant treatment (chemotherapy, hormonal therapy and radiotherapy) were retrieved from the routine reports.

In the present study, a consecutive series (including symptomatic non-screened patients) were examined. As a result many of the cancers were relatively advanced, and the proportions of grade III and node positive cancers were relatively high. Also, the patients included in this study did not receive neoadjuvant therapy or adjuvant anti-HER-2 therapy.

Oestrogen receptors (ER), progesterone receptors (PR), HER-2 status and Ki-67 immunohistochemical analyses were performed as previously described, and the results of visual scoring were used in this study ([@bib18]). The inclusion of ductal breast cancers only was to limit the potential confounding effects of other tumour types on the analysis in the present study.

Institutional Review Board approval for use of human tissue in this study was given by the Research Ethics Committee of the North Glasgow University Hospitals NHS Trust.

Methods
-------

### Tissue micro array construction

Tissue microarrays (TMA) were used in this study. The TMA samples were taken from the tumour-rich area of each specimen, and TMAs were constructed in triplicate, using 0.6 mm^2^ cores, to account for intra-tumour disease heterogeneity as previously described ([@bib22]).

### Slide scanning and scoring

Stained slides were scanned at objective magnification × 40 using a Hamamatsu NanoZoomer (Hertfordshire, UK). Assessment of tumour inflammatory cell infiltrate was performed on a computer monitor using Slidepath Tissue IA system version 3.0 (Dublin, Ireland).

### Assessment of tumour inflammatory infiltrate

Full-section haematoxylin and eosin slides for the 338 patients were used to score peri-tumoural inflammatory cell infiltrate according to Klintrup criteria. Klintrup scoring of slides was carried out as previously described. Briefly, tumours were scored on a 4-point scores based on appearances at the edge of tumour invasion. A score of 0 signified that there were no inflammatory cells at tumour\'s invasive margin; score 1, indicated a mild and patchy inflammatory cells; score 2, denoted a prominent band-like inflammatory reaction at the invasive margin and score 3, revealed a florid cup-like inflammatory infiltrate at the invasive edge with frequent destruction of cancer cell islands ([@bib13]). Full-section haematoxylin and eosin slides were also used to score the proportions of neutrophils and lymphocytes as previously reported. Briefly, neutrophils and lymphocytes were estimated in a minimum of 4 to a maximum of 12 fields ( × 40, 0.6 mm in diameter) at the invasive margin on full-section haematoxylin and eosin slides ([@bib19]). The Klintrup criteria were described as absent or present. In light of specific staining of macrophages and lymphocytes subsets, this is now termed low- and high-grade Klintrup criteria, respectively. TMA and immunohistochemistry were utilised to assess macrophages as previously reported ([@bib19]).

### Immunohistochemistry for lymphocytes subsets

Immunoreactivity to anti-CD4+, CD8+, CD20+ and CD138+ antibodies was determined in 40 cases by using full-faced tissue sections. Tissue microarrays (TMAs) were also utilised to assess T and B lymphocyte subsets for the 338 patients. Freshly cut 2.5-*μ*m-thick breast cancer full-faced tissue sections and TMAs were stained for CD4+, CD8+, CD20+ and CD138+. Sections and cores were dewaxed and rehydrated. Antigen retrieval for CD4+, CD8+ and CD138+ were performed by keeping the section in Tris-EDTA buffer (pH 8) in pressure cooker for 7 min, whereas antigen retrieval for CD20+ was performed by keeping the section in 10 mmol l^−1^ sodium citrate buffer (pH 6.0) in pressure cooker for 20 min ([@bib16]). Endogeneous peroxidise was locked by incubation in 3% hydrogen peroxide for 20 min. The cores were then incubated with the normal horse serum at dilution 1 : 10 for 30 min at 25 °C to block non-specific binding sites. The primary antibodies for CD4+ (monoclonal mouse anti-human, CD4+, Clone 4B12, Code VP- C319, Vector, Peterborough, UK) added with dilution 1 : 10 for 30 min at 25 °C, for CD8+ (monoclonal mouse anti-human, CD8+, Clone CD8/ 144B, Code M 7103, DAKO, Glostrup, Denmark) added with dilution 1 : 400 at 4 °C for overnight, for CD20+ (monoclonal mouse anti-human, CD29cy, Clone L26, Code M0755, Dako, Glostrup, Denmark) added with dilution 1 : 300 for 30 min at 25 °C and that for CD138+ (monoclonal mouse anti-human, CD138+, Clone MI15, Code M 7228, DAKO, Glostrup, Denmark) added with dilution 1 : 100 at room temperature for 30 min. Sites of binding were detected using the Envision technique (DAKO code K5007, Glostrup, Denmark) with DAB (3-3′ diaminobenzidine, Vector code SK 4001, USA), a chromogenic substrate, according to the manufacturer\'s instruction. Cores were counterstained with haematoxylin, dehydrated and mounted with DPX. Two full sections of the tonsil tissue were used as positive and negative controls for each set of staining, since tonsil had previously shown to have a high CD4 +, CD8+, CD20+ and CD138+ content, by immunohistochemical staining.

Assessment of CD4+, CD8+, CD20+ and CD138+ and scoring in full-faced tissue sections and TMA was based on a modification of the method described by ([@bib17]; [@bib16]) in which the number of T and B lymphocytes was counted. In the full-faced tissue sections, CD4+, CD8+, CD20+ and CD138+ were counted in three × 20 fields, and the mean for the three fields was calculated. In TMA, CD4+, CD8+, CD20+ and CD138+ were counted in the three cores and, as each tumour had triplicate cores, the mean count for each carcinoma was taken as a final score. The means for the three fields in full-faced sections for CD4+, CD8+, CD20+ and CD138+ were compared with the mean of three cores for CD4+, CD8+, CD20+ and CD138+ in TMA for the same patients. The Interclass Correlation Coefficients (ICCCs) were 0.88, 0.99, 0.80 and 0.80 for CD4+, CD8+, CD20+ and CD138+, respectively, which indicates excellent agreement.

One hundred and eighty cores were independently scored for CD4+, CD8+ and CD20+ by two observers, ZM and BE, and for CD138+ by ZM and JG blinded to patient outcome and the other observer\'s score. The ICCCs were 0.90 for CD4+, 0.90 for CD8+, 0.86 for CD20+ and 0.90 for CD138+, which indicates excellent agreement. The author (ZM) then scored all slides, and these data were used in subsequent analysis.

Patients underwent regular follow-up (3 months, 6 months and then yearly to five years) with yearly CT scanning and regular X-ray mammography surveillance until 10 years post surgery. Information on date and cause of death was checked with that received by the Cancer Registry system and the Registrar General (Scotland).

Statistical analysis
--------------------

The inter-observer interclass correlation coefficient was performed using Reliability analysis. Inter-relationships between variables were assessed using contingency table analysis with the chi-squared test for trend as appropriate. As there appears to be no consistent and well defined cutoffs for CD4+ T-lymphocytic infiltrate, CD8+ T-lymphocytic infiltrate, CD20+ B-lymphocytic infiltrate and CD138+ B-lymphocytic infiltrate, the data were grouped into tertiles (0, 1--34 and ⩾35) for CD4+ T-lymphocytic infiltrate, (⩽4, 5--39 and ⩾40) for CD8+ T-lymphocytic infiltrate, (0, 1--12 and ⩾13) for CD20+ B-lymphocytic infiltrate and (0, 1--9 and ⩾10) for CD138+ B-lymphocytic infiltrate ([Figure 1](#fig1){ref-type="fig"}). On inspection of the survival curves for these tertiles ([Figure 2A--D](#fig2){ref-type="fig"}), there was no association between CD4+ T-lymphocytic infiltrate, CD20+ B-lymphocytic infiltrate and cancer-specific survival ([Figure 2A and C](#fig2){ref-type="fig"}), there was a significant association between CD8+ T-lymphocytic infiltrate and improved cancer-specific survival ([Figure 2B](#fig2){ref-type="fig"}) and there was significant association between CD138+ B-lymphocytic infiltrate and poorer cancer-specific survival ([Figure 2D](#fig2){ref-type="fig"}). Also, the defined and validated cutoffs for CD8+ ([@bib1]; [@bib17]; [@bib15]) and CD20+ ([@bib16]) alongside the tertiles were used in the current analysis.

Univariate and multivariate survival analysis with calculation of hazard ratios (HR) and 95% confidence interval (95% CI) were performed using a Cox proportional-hazards model. A stepwise backward procedure was used to derive a final model of the variables that had a significant independent relationship with survival. During this analysis, the proportionality assumptions in the Cox model were explored using a log minus log visual inspection and were found to be satisfactory. The relationship between the clinico-pathological characteristics and cancer-specific survival was also assessed using Kaplan--Meier plots. No variable examined in such analysis had more than 17% of total observations missing. Deaths up to March 2010 were included in the analysis. Because of the number of statistical comparisons, a *P*-value \<0.01 was considered to be significant. All statistical analysis was performed using SPSS software version 19 (SPSS Inc., Chicago, IL, USA)

Results
=======

Baseline clinico-pathological characteristics of the patients with primary operable ductal invasive breast cancer (*n*=338) are shown in [Table 1](#tbl1){ref-type="table"}.

Relationships between generalised inflammatory cells infiltrate and clinico-pathological characteristics are shown in [Table 2](#tbl2){ref-type="table"}. Patients with high-grade tumour inflammatory cell infiltrate (91%) had higher tumour grade (*P*\<0.05), more ER-negative tumours (*P*\<0.01), more PR-negative tumours (*P*\<0.05), higher percentage of neutrophil cell infiltrate at the invasive margin (*P*\<0.01), higher number of macrophage cell infiltrate at the invasive margin (*P*\<0.001), higher percentage of lymphocyte cell infiltrate at the invasive margin (*P*\<0.001), higher percentage of plasma cell infiltrate at the invasive margin (*P*\<0.01), higher number of CD8+ T-lymphocytic infiltrate (*P*\<0.01), higher number of CD20+ T-lymphocytic infiltrate (*P*\<0.01) and had a longer cancer-specific survival (*P*\<0.01).

In order to account for the potential confounding effect of the extent of inflammatory infiltrate on the relationship of lymphocyte subsets and survival, the subsequent analysis was performed in patients who had a significant inflammatory infiltrate.

Minimum follow-up was 26 months; the median follow-up of the survivors was 164 months. In the patients with inflammatory infiltrate 73 patients developed recurrence, 14 local, 44 distant and 4 both, 144 patients died, 65 from their disease.

The relationship between clinico-pathological characteristics of patients with primary operable invasive ductal breast cancer and had high-grade inflammatory infiltrate and recurrence-free survival was examined. On univariate survival analysis, tumour neutrophil infiltrate (HR: 1.89, 95% CI: 1.12--3.19, *P=*0.016), tumour plasma cell infiltrate (HR: 2.96, 95% CI: 0.17--0.50, *P\<*0.001) and tumour CD138+ B-lymphocytic infiltrate (HR: 1.92, 95% CI: 1.37--2.68, *P\<*0.001) were significantly associated with poorer recurrence-free survival. Tumour lymphocytic infiltrate (HR: 0.30, 95% CI: 0.17--0.51, *P\<*0.001), lymphocyte infiltrate/ tumour plasma cell infiltrate ratio (HR: 0.51, 95% CI: 0.35--0.74, *P\<*0.001), tumour CD8+ T-lymphocytic infiltrate (tertiles) (HR: 0.67, 95% CI: 0.48--0.93, *P=*0.018) and tumour CD8+ T-lymphocyte infiltrate/ tumour CD138+ B-lymphocytic infiltrate ratio (HR: 0.39, 95% CI: 0.26--0.59, *P\<*0.001) were significantly associated with improved recurrence-free survival. On multivariate survival analysis, tumour CD8+ T-lymphocyte infiltrate/ tumour CD138+ B-lymphocytic infiltrate ratio (HR: 0.45, 95% CI: 0.29--0.70, *P\<*0.001) was independently associated with improved recurrence-free survival and tumour plasma cell infiltrate (HR: 2.70, 95% CI: 1.30--5.58, *P=*0.007) was significantly associated with poorer recurrence-free survival. When the established pathological prognostic factors including age, tumour size, grade, lymph node status, PR status, HER-2 status, Ki-67 proliferative activities and lymphovascular invasion were included in the multivariate model, lymphovascular invasion (HR: 4.86, 95% CI: 2.10--11.24, *P*\<0.001) and plasma cell infiltrate (HR: 2.43, 95% CI: 1.22--4.82, *P=*0.011) were significant independent predictors of poorer recurrence-free survival. Tumour CD8+ T-lymphocyte infiltrate/ tumour CD138+ B-lymphocytic infiltrate ratio (HR: 0.40, 95% CI: 0.26--0.62, *P\<*0.001) was significant independent predictor of improved recurrence-free survival for patients with high-grade inflammatory infiltrate primary operable invasive breast cancer.

The relationships between clinico-pathological characteristics of patients primary operable invasive breast cancer and had high-grade inflammatory infiltrate and cancer-specific survival are shown in [Table 3](#tbl3){ref-type="table"}. On univariate survival analysis, tumour macrophage infiltrate (*P\<*0.05), tumour lymphocytic infiltrate (*P*\<0.001), tumour lymphocyte infiltrate/ tumour plasma cell infiltrate ratio (*P*\<0.001), tumour CD8+ T-lymphocytic infiltrate (tertiles) and tumour CD8+ T-lymphocyte infiltrate/ tumour CD138+ B-lymphocytic infiltrate ratio (*P*\<0.001) were significantly associated with improved cancer-specific survival. Tumour neutrophil infiltrate (*P\<*0.05), tumour plasma cell infiltrate (*P\<*0.001) and tumour CD138+ B-lymphocytic infiltrate (*P\<*0.001) were significantly associated with poorer cancer-specific survival. On multivariate survival analysis, lymphocytic infiltrate (*P*\<0.001) and tumour CD8+ T-lymphocyte infiltrate/ tumour CD138+ B-lymphocytic infiltrate ratio (*P*\<0.001) were independently associated with improved cancer-specific survival. When the established pathological prognostic factors including age, tumour size, grade, lymph node status, PR status, HER-2 status, Ki-67 proliferative activities and lymphovascular invasion were included in the multivariate model ([Table 4](#tbl4){ref-type="table"}), lymphovascular invasion (*P*\<0.001) was significant independent predictors of poorer cancer-specific survival, and lymphocytic infiltrate (*P*\<0.001) and tumour CD8+ T-lymphocyte infiltrate/ tumour CD138+ B-lymphocytic infiltrate ratio (*P*\<0.001) were significant independent predictors of improved cancer-specific survival for patients with high-grade inflammatory infiltrate primary operable invasive breast cancer.

The inter-relationships between the different inflammatory cell types and clinico-pathological characteristics for patients with primary operable invasive ductal breast cancer are shown in [Table 5](#tbl5){ref-type="table"}. Tumour grade was directly associated with tumour macrophage infiltrate (*P*\<0.001) and CD8+ and CD138+ infiltrates (all *P*\<0.001) and inversely associated with the percentage of tumour lymphocyte infiltrate (*P*\<0.001). The expression of ER was directly associated with the percentage of tumour lymphocyte infiltrate (*P*\<0.001) and inversely associated with CD8+ (*P*\<0.01) and CD138+ infiltrates (*P*\<0.001). The expression of PR was directly associated with the percentage of tumour lymphocyte infiltrate (*P*\<0.001) and inversely associated with CD138+ infiltrates (*P*\<0.01). The expression of HER-2 was directly associated with CD8+ (*P*\<0.001) and inversely associated with CD138+ infiltrates (*P*\<0.001). Tumour macrophage infiltrate was directly associated with tumour CD8+ (*P*\<0.001) and CD138+ (*P*\<0.01) infiltrates. Tumour CD8+ T-lymphocyte infiltrate was directly associated with CD138+ (*P*\<0.001) infiltrates.

Discussion
==========

The results of the present study show that the majority (91%) of patients with primary operable invasive ductal breast cancer had high-grade inflammatory infiltrate and that most inflammatory cell types were greater in number compared with a low-grade inflammatory cell infiltrate. In particular, adaptive immune response components especially CD8+ T lymphocytes were greater in number. For example, the majority of T-lymphocytes were CD8+T lymphocytes rather than CD4+ T lymphocytes as might be expected from their circulating numbers (the CD4+/CD8+ ratio was 1 : 3 in contrast to the expected ratio of 2 : 1). When the prognostic value of the lymphocyte subsets were examined in multivariate survival analysis, it was of interest that CD8+ and CD138+ infiltration displaced tumour-based factors including grade and hormone status as prognostic factors. Taken together, these results would indicate that the majority of patients with primary operable invasive ductal breast cancer have evidence of a high-grade inflammatory cell infiltrate and that components of this response, representing a coordinated immune response, have prognostic value superior to that of tumour-based factors.

With reference to the present observation that a high CD138+ B-lymphocytic infiltrate was associated with poorer cancer survival, it is well recognised that B lymphocytes contribute to cellular immunity by serving as antigen-presenting cells (APCs) and/or by providing co-stimulatory signals to T-lymphocytes ([@bib8]). Therefore, it may be that inappropriately large numbers of such cells promote tumour progression or alternatively that large highly proliferating tumours bring about downregulation and upregulation of T- and B-lymphocytic responses, respectively. However, the former explanation is a more likely as neither cell type was significantly associated with tumour size of the Ki-67-labelling index and that both cell types were associated with grade. Indeed, chronic activation of B-lymphocytes can be deleterious, as evidenced by their association with several pathologic disease states (rheumatoid arthritis and other autoimmune diseases) and some cancer types ([@bib10]; [@bib27]).

The basis of the relationship between tumour grade, tumour macrophage, CD8+ and CD138+ infiltrates and cancer outcome is not clear. One hypothesis would be that the tumour necrosis may have part in these relationships as rapidly growing tumours quickly outgrow their own blood supply, becoming necrotic, and this results in the production of stress protein including chemokines and cytokines that attract specific inflammatory cells. Indeed, [@bib5] and [@bib4] reported that tumours with extensive necrosis contained more inflammatory cells . Moreover, [@bib24] reported that the impact of tumour necrosis on colorectal cancer survival may be explained by close relationships with host inflammatory responses . Therefore, further work is required to examine the relationship between tumour necrosis, the nature of the inflammatory cell infiltrate and survival in patients with primary operable invasive breast cancer.

The results of the present study build on our previous work using H&E ([@bib19]) and indicate that the ratio between the lymphocytic/plasma cell infiltrate using more sophisticated immunohistochemical techniques has an independent prognostic role, superior to individual inflammatory cell types. If this work was to be confirmed in other cohorts it would enable the definition of a reliable scoring system to help rationalise the enormous amount of work that has and is continuing to be carried out into the nature of the inflammatory cell infiltrate in patients with breast cancer. This ratio can be readily standardised, using automated counting systems, and can be carried out in both H&E slides and also IHC slides. Finally it may provide a useful therapeutic target.

The results of the present study may also shed some light on the nature of the local inflammatory response, as they would suggest that a coordinated response between lymphocytes and plasma cells might have a profound effect on outcome. Indeed, it is well recognised that B lymphocytes contribute to cellular immunity by serving as antigen-presenting cells (APCs) and/or by providing costimulatory signals to T lymphocytes ([@bib8]). For example, as the ratio of CD8 T-lymphocytes to CD138 B-lymphocytes increased (from ⩽3 to 4--9 to ⩾10), there was an approximately five-fold improvement in recurrence-free and cancer-specific survival. These results may suggest that a dysregulated immune response with downregulation and upregulation of T- and B-lymphocytic responses, respectively ([@bib10]; [@bib27]).

There are striking similarities to recent work in colorectal cancer that has resulted in a profusion of immune-based prognostic scores ([@bib11]; [@bib2]). With reference to breast cancer, [@bib9] have proposed the combination of a low CD68+ and low CD4+ and high CD8+ for predicting improved survival in patients with operable breast cancer . The results of the present study, in patients with a high grade inflammatory cell infiltrate, confirm the utility of high CD8+ T-lymphocytic infiltrate but not a low CD68+ macrophage infiltrate or a low CD4+ T-lymphocytic infiltrate having independent associations with improved survival in patients with operable ductal breast cancer. Interestingly, a high CD138+ B-lymphocytic infiltrate was also shown to be associated with poorer outcome and had independent prognostic value. The significance of the present discrepant findings are as yet unclear. However, they do point clearly to the importance of immune context and the need to assess the extent of the inflammatory cell infiltrate before carrying out more sophisticated analysis on particular inflammatory cell types.

The present study has a number of limitations. In particular, the analysis of the inflammatory cell infiltrate was undertaken using visual quantitative and semi-quantitative techniques. To minimise the risk of measurement bias, two independent observers examined the same cores or sections before assigning an overall score. High levels of independent inter-observer agreement in the assessment of all examined factors suggest that these techniques are reliable. Also, the limitation of whether a small core sample used in the present TMA was representative of the entire tumour was examined, using a pilot comparison study of at least 30 full-faced breast cancer tissue sections. Also, in the present study, defined and validated thresholds for CD8+ and CD20+ were included to thoroughly examine their relationship with the survival. Clearly, the novel findings of the present study require independent validation in other centres and in contemporary cohorts of patients.

In summary, the results of the present study indicate that, in ductal breast cancer, the majority of patients have a high-grade inflammatory cell infiltrate, there are relationships between tumour grade, tumour macrophage, CD8+ and CD138+ infiltrates and these inflammatory cell types are independent predictors of cancer survival in patients primary operable invasive ductal breast cancer. Further, the ratio between lymphocyte and plasma cell infiltrate (H&E and IHC) had independent prognostic value.
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![**(**A**) CD4+, (**B**) CD8+, (**C**) CD20+ and (**D**) CD138+ immunohistochemical staining in invasive ductal breast cancer ( × 20).**](bjc2013493f1){#fig1}

![**The relationship between CD4+T-lymphocytic infiltrate (**A**), CD8+ T-lymphocytic infiltrate (**B**), CD20+ B-lymphocytic infiltrate (**C**) and CD138+ B-lymphocytic infiltrate (**D**) and cancer-specific survival in all patients with invasive ductal breast cancer.**](bjc2013493f2){#fig2}

###### Clinico-pathological characteristics of patients with primary operable invasive ductal breast (*n*=338)

  **Clinico-pathological characteristics**                                                            **Patients (*****n***)
  -------------------------------------------------------------------------------------------- -------------------------------------
  Age (⩽50/ \>50 years)                                                                                 95 (28%)/243 (72%)
  Size (⩽20/ 21--50/ \>50 mm)                                                                       186 (55%)/142 (42%)/9 (3%)
  Grade (I/II/III)                                                                                 60 (18%)/137 (41%)/141 (42%)
  Involved lymph node (0/1--3/\>3)                                                                  171 (51%)/99 (29%)/64 (19%)
  Oestrogen -receptor status (ER--/ER+)                                                                 112 (33%)/224 (66%)
  Progesterone -receptor status (PR--/PR+)                                                              180 (53%)/154 (46%)
  HER-2 status (HER-2−/HER-2+)                                                                          276 (82%)/58 (17%)
  Ki-67 status (Low Ki-67/high Ki-67)                                                                   246 (73%)/89 (26%)
  Lymphovascular invasion (absent / present)                                                            145 (43%)/134 (40%)
  General inflammatory infiltrate (absent / present)                                                     21 (6%)/306 (91%)
  **Innate immune response**                                                                   
  Tumour neutrophil infiltrate (absent / present)                                                       209 (62%)/118 (35%)
  Tumour macrophage infiltrate (tertiles)                                                          85 (25%)/113 (33%)/122 (36%)
  **Adaptive immune response**                                                                 
  Tumour lymphocyte infiltrate (Low/high)                                                               132 (39%)/195 (58%)
  Tumour plasma cell infiltrate (Low/high)                                                              222 (66%)/105 (31%)
  Tumour CD4+ T-lymphocytic infiltrate (median, range)                                                      8 (0--425)
  Tumour CD8+ T-lymphocytic infiltrate (median, range)                                                      29 (0--342)
  Tumour CD20+ B-lymphocytic infiltrate (median, range)                                                     1 (0--328)
  Tumour CD138+ B-lymphocytic infiltrate (median, range)                                                    1 (0--235)
  Loco-regional treatment (Lumpectomy+radiotherapy/mastectomy+radiotherapy)                             118 (35%)/220 (65%)
  Systemic treatment (ER-based treatment) (hormonal/hormonal+chemotherapy/chemotherapy/none)    171 (51%)/79 (23%)/69 (20%)/13 (4%)

###### The relationship between general inflammatory infiltrate and clinico-pathological characteristics of patients with primary operable invasive ductal breast cancer

                                                                                                **Low-grade inflammatory cell infiltrate (*****n*****=21)**   **High-grade inflammatory cell infiltrate (*****n*****=306)**  **(*P*-value)**
  -------------------------------------------------------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------- -----------------
  Age (⩽50/\>50 years)                                                                                                     3/18                                                          88/218                              0.153
  Size (⩽20/21--50/\>50 mm)                                                                                               14/7/0                                                        167/129/9                            0.233
  Grade (I/II/III)                                                                                                        6/12/3                                                       53/116/137                            0.013
  Involved lymph node (0/1--3/\>3)                                                                                        12/6/3                                                        152/91/59                            0.491
  Oestrogen-receptor status (ER−/ER+)                                                                                      0/21                                                          111/193                             0.001
  Progesterone-receptor status (PR−/PR+)                                                                                   7/14                                                          168/134                             0.048
  HER-2 status (HER-2−/HER-2+)                                                                                             18/3                                                          248/54                              0.677
  Ki-67 status (Low Ki-67/high Ki-67)                                                                                      16/5                                                          220/83                              0.721
  Lymphovascular invasion (Absent/present)                                                                                 14/6                                                          128/122                             0.106
  **Innate immune response**                                                                                                                                                                                                 
  Tumour neutrophil infiltrate (median, range)                                                                           0 (0--20)                                                      0 (0--40)                            0.004
  Tumour macrophage infiltrate (median, range)                                                                         119 (16--450)                                                  187 (34--619)                          \<0.001
  **Adaptive immune response**                                                                                                                                                                                               
  Tumour lymphocyte infiltrate (median, range)                                                                               0                                                         98 (0--100)                           \<0.001
  Tumour plasma cell infiltrate (median, range)                                                                              0                                                          1 (0--90)                            \<0.001
  Tumour CD4+ T-lymphocytic infiltrate (median, range)                                                                   5 (0--40)                                                     9 (0--425)                            0.054
  Tumour CD8+ T-lymphocytic infiltrate (median, range)                                                                  10 (0--52)                                                     42 (0--342)                           0.001
  Tumour CD20+ B-lymphocytic infiltrate (median, range)                                                                  0 (0--7)                                                      1 (0--328)                            0.001
  Tumour CD138+ B-lymphocytic infiltrate (median, range)                                                                 0 (0--7)                                                      1 (1--235)                            0.187
  Loco-regional treatment (Lumpectomy+radiotherapy/mastectomy+radiotherapy)                                                8/13                                                          107/199                             0.772
  Systemic treatment (ER-based treatment) (hormonal/hormonal+chemotherapy/chemotherapy/none)                             14/5/1/1                                                     152/70/66/12                           0.125
  Cancer-specific survival (months)[a](#t2-fn1){ref-type="fn"}                                                         113 (78--148)                                                 150 (143--156)                          0.005

Mean (95%CI).

###### The relationship between components of inflammatory cell infiltrate of patients with high grade inflammatory cell infiltrate primary operable invasive ductal breast cancer and cancer-specific survival

                                                                                **Univariate survival analysis**   **Multivariate survival analysis**                       
  ----------------------------------------------------------------------------- ---------------------------------- ------------------------------------ ------------------- ---------
  **Innate immune response**                                                                                                                                                
  Tumour neutrophil infiltrate (Low/high)                                       1.78 (1.09--2.90)                  0.020                                                    0.800
  Tumour macrophage infiltrate (tertiles)                                       0.71 (0.51--0.98)                  0.035                                                    0.170
  **Adaptive immune response**                                                                                                                                              
  Tumour lymphocyte infiltrate (Low/high)                                       0.13 (0.07--0.23)                  \<0.001                              0.21 (0.20--0.47)   \<0.001
  Tumour plasma cell infiltrate (Low/high)                                      5.54 (3.24--9.46)                  \<0.001                                                  0.956
  Tumour lymphocyte infiltrate/Tumour plasma cell infiltrate ratio (tertiles)   0.33 (0.22--0.48)                  \<0.001                                                  0.330
  Tumour CD4+ T-lymphocytic infiltrate (tertiles)                               0.96 (0.71--1.29)                  0.780                                                     
  Tumour CD8+ T-lymphocytic infiltrate (\<2/⩾2)                                 0.89 (0.32--2.43)                  0.813                                                     
  Tumour CD8+ T-lymphocytic infiltrate (tertiles)                               0.55 (0.40--0.76)                  \<0.001                                                  0.597
  Tumour CD20+ B-lymphocytic infiltrate (\>5)                                   0.85 (0.50--1.45)                  0.555                                                     
  Tumour CD20+ B-lymphocytic infiltrate (tertiles)                              0.91 (0.66--1.24)                  0.534                                                     
  Tumour CD138+ B-lymphocytic infiltrate (tertiles)                             1.92 (1.41--2.62)                  \<0.001                                                  0.422
  Tumour CD8+ infiltrate/Tumour CD138+ infiltrate ratio (tertiles)              0.40 (0.27--0.59)                  \<0.001                              0.46 (0.30--0.70)   \<0.001

###### The relationship between clinic-pathological characteristics of patients with high-grade inflammatory cell infiltrate primary operable invasive ductal breast cancer and cancer-specific survival

                                                                                 **Univariate survival analysis**  **Multivariate survival analysis**                        
  ----------------------------------------------------------------------------- ---------------------------------- ------------------------------------ -------------------- ---------
  Age (\<50/\>50 years)                                                                 1.43 (0.82--2.52)          0.211                                                      
  Size (⩽20/21--50/\>50 mm)                                                             2.57 (1.67--3.95)          \<0.001                                                   0.064
  Grade (I/II/III)                                                                      1.84 (1.25--2.68)          0.002                                                     0.299
  Involved lymph node (0/1--3/\>3)                                                      2.45 (1.80--3.33)          \<0.001                                                   0.255
  Oestrogen-receptor status status (ER−/ER+)                                             0.41(0.25--0.66)          \<0.001                                                   0.956
  Progesterone-receptor status (PR−/PR+)                                                 0.35(0.20--0.61)          \<0.001                                                   0.713
  HER-2 status (HER-2−/HER-2+)                                                          1.66 (0.93--2.95)          0.086                                                     0.678
  Ki-67/ MIB1 proliferation index (Low Ki-67/high Ki-67)                                1.76 (1.06--2.91)          0.028                                                     0.371
  Lymphovascular invasion (Absent/present)                                              4.82 (2.48--9.34)          \<0.001                               5.66 (1.92--16.65)  0.002
  **Innate immune response**                                                                                                                                                 
  Tumour macrophage infiltrate (tertiles)                                               0.71 (0.51--0.98)          0.035                                                     0.056
  **Adaptive immune response**                                                                                                                                               
  Tumour lymphocyte infiltrate (Low/high)                                               0.13 (0.07--0.23)          \<0.001                               0.21 (0.09--0.50)   \<0.001
  Tumour lymphocyte infiltrate/tumour plasma cell infiltrate ratio (tertiles)           0.33 (0.22--0.48)          \<0.001                                                   0.245
  Tumour CD8+ T-lymphocytic infiltrate (tertiles)                                       0.55 (0.40--0.76)          \<0.001                                                   0.851
  Tumour CD138+ B-lymphocytic infiltrate (tertiles)                                     1.92 (1.41--2.62)          \<0.001                                                   0.194
  Tumour CD8+ infiltrate/tumour CD138+ infiltrate ratio (tertiles)                      0.40 (0.27--0.59)          \<0.001                               0.48 (0.31--0.76)   0.002

###### Inter-relationships between the clinicopathological characteristics of patients with high grade inflammatory cell infiltrate primary operable invasive ductal breast cancer

                                                     **Grade (*P*-value)**   **Involved lymph node (*P*-value)**   **ER status (*P*-value)**   **PR status (*P*-value)**   **HER-2 status (*P*-value)**   **Ki-67 status (*P*-value)**   **LVI (*P*-value)**   **CD68+ (*P*-value)**   **Tumour lymphocytic infiltrate (*P*-value)**   **CD8+ T-lymphocytic infiltrate (*P*-value)**   **CD138+ B-lymphocytic infiltrate**
  ------------------------------------------------- ----------------------- ------------------------------------- --------------------------- --------------------------- ------------------------------ ------------------------------ --------------------- ----------------------- ----------------------------------------------- ----------------------------------------------- -------------------------------------
  Size (⩽20/ 21--50/\>50 mm)                               **0.001**                     **\<0.001**                       **0.007**                     0.028                        0.195                          0.059                   **\<0.001**               0.924                               0.109                                           0.540                                      0.134
  Grade (I/II/III)                                                                          0.024                         **\<0.001**                 **\<0.001**                  **\<0.001**                     **0.002**                  **0.001**              **0.006**                          **\<0.001**                                     **\<0.001**                                **\<0.001**
  Involved lymph node (0/1--3/\>3)                                                                                           0.031                       0.308                        0.016                          0.357                   **\<0.001**               0.923                               0.017                                           0.911                                      0.102
  ER status (ER-/ER+)                                                                                                                                 **\<0.001**                  **\<0.001**                       0.105                      0.014                  0.132                            **\<0.001**                                      **0.003**                                 **\<0.001**
  PR status (PR-/PR+)                                                                                                                                                              **\<0.001**                       0.239                      0.090                  0.647                            **\<0.001**                                        0.205                                    **0.001**
  HER-2 status (HER-2 -/HER-2+)                                                                                                                                                                                      0.159                    **0.002**                0.187                               0.197                                           0.771                                   **\<0.001**
  Ki-67 (Low Ki-67/High Ki-67)                                                                                                                                                                                                                  0.239                  0.151                               0.170                                           0.075                                      0.306
  Lymphovascular invasion (LVI-/LVI+)                                                                                                                                                                                                                                  0.829                               0.017                                           0.567                                      0.089
  Tumour macrophage infiltrate (tertiles)                                                                                                                                                                                                                                                                  0.870                                        **\<0.001**                                 **0.007**
  Tumour lymphocyte infiltrate (Low/high)                                                                                                                                                                                                                                                                                                                  0.969                                      0.024
  Tumour CD8+ T-lymphocytic infiltrate (tertiles)                                                                                                                                                                                                                                                                                                                                                  **\<0.001**

*P*-values \<0.01 are shown in bold face.
